Compensatory hallucinogenesis across three neuropsychiatric disorders: a Bayesian account
Brain Communications · 02.01.2026 · 8 (1)
DOI: 10.1093/braincomms/fcag001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Communications, online erschienen am 07.01.2026. Verfasst von Raina Vin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, Yale University, New Haven, CT 06510, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 330 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yale Center for Brain Mind Health Seed, National Institute of Neurological Disorders and Stroke (NINDS) Multimodal Delineation of Neurodegenerative Mechanisms T32 training.
Abstract (Originalsprache)
Emerging evidence suggests that hallucinations may arise because of an over-reliance on prior knowledge during perception. While best established in psychosis-spectrum illness, data also support the presence of this abnormality in other hallucination-prone neuropsychiatric illnesses that vary in their association with disruption of sensory circuits. In this piece, we ask whether an over-weighting of expectations may be conceived of as a compensatory response to degraded incoming sensory information. We make the case that visual hallucinogenesis across a wide array of neuropsychiatric disorders can be captured within a common Bayesian computational framework, as a compensatory response to sensory signal disruptions at different levels of the visual processing hierarchy. We focus on three specific disorders (Charles Bonnet syndrome, dementia with Lewy Bodies and psychosis) with prominent visual hallucinations and highlight the fact that these disorders describe a spectrum of visual impairment where the overtness and localization of the visual processing disruption is reflected in the characteristics of the emergent visual hallucinations. We examine how discrete sensory disruptions in Charles Bonnet syndrome translate to hallucinations via known circuits, and then how different disruptions in dementia with Lewy Bodies and Schizophrenia may lead to hallucinations with distinct phenomenology, comorbidities and circuit involvement. Finally, we appeal to emerging computational theories to unite these observations under a common conceptual umbrella. Taken together, this work presents a means of understanding how sensory disruptions could interact with other aspects of cognitive and neural architecture to produce hallucinations across neuropsychiatric disease. It is our hope that this framework will help in efforts to identify pathophysiologically distinct patient subgroups and new pharmacological and circuit-based interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yale School of Medicine, Yale University, New Haven, CT 06510, USA.
ORCID-Profile: Hae Young Yi, Carolyn Fredericks
Förderung
- Yale Center for Brain Mind Health Seed
- National Institute of Neurological Disorders and Stroke (NINDS) Multimodal Delineation of Neurodegenerative Mechanisms T32 training
Zitieren
APA
Vin, R., Galbraith, J., Seabury, R., Yi, H. Y., Hernández-Busot, G., Oland, L., Epie, B., Trainer, A., Fredericks, C., & Powers, A. R. (2026). Compensatory hallucinogenesis across three neuropsychiatric disorders: a Bayesian account. Brain Communications, 8(1). https://doi.org/10.1093/braincomms/fcag001
Vancouver
Vin R, Galbraith J, Seabury R, Yi HY, Hernández-Busot G, Oland L, et al. Compensatory hallucinogenesis across three neuropsychiatric disorders: a Bayesian account. Brain Communications. 2026;8(1). doi:10.1093/braincomms/fcag001
BibTeX
@article{Vin2026,
author = {Vin, Raina and Galbraith, Jordan and Seabury, Rashina and Yi, Hae Young and Hernández-Busot, Gabriela and Oland, Lucas and Epie, Boris and Trainer, Anne and Fredericks, Carolyn and Powers, Albert R},
title = {Compensatory hallucinogenesis across three neuropsychiatric disorders: a Bayesian account},
journal = {Brain Communications},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/braincomms/fcag001}
}
EUVIMED